{"entity":{"id":"nct07680439","kind":"trial","name":"Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).","aka":[],"tldr":"A phase 2 trial of BCB-276 in diffuse midline glioma, h3 k27-altered, run by BrainChild Bio, Inc, now recruiting.","summary":"Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). is a phase 2 interventional study registered as NCT07680439 by BrainChild Bio, Inc, with 75 participants planned, started 2026-08 and due to reach its primary completion in 2028-10. Interventions recorded: BCB-276. Conditions listed: Diffuse Intrinsic Pontine Glioma, DIPG, Brain Tumor, CNS Tumor. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07680439","url":"https://clinicaltrials.gov/study/NCT07680439"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dipg-dmg"],"sections":[],"technologies":[],"targets":[],"drugs":["bcb-276"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07680439","phase":"2","setting":"A Phase 2 Pivotal Study of BCB-276, a B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma","sponsor":"BrainChild Bio, Inc","enrolled":75,"outcomes":[]},"route":"/trials/nct07680439/","neighbours":{"cancer":[{"id":"dipg-dmg","kind":"cancer","name":"Diffuse midline glioma, H3 K27-altered (including DIPG)","route":"/cancers/dipg-dmg/"}],"drug":[{"id":"bcb-276","kind":"drug","name":"BCB-276","route":"/drugs/bcb-276/"}]}}